BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2809813
Number of visits today
1439
Number of downloads
2061627
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. IJMS 2022;23:3668. [DOI: 10.3390/ijms23073668] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Gao Y, Hua R, Peng K, Yin Y, Zeng C, Guo Y, Wang Y, Li L, Li X, Qiu Y, Wang Z. High-starchy carbohydrate diet aggravates NAFLD by increasing fatty acids influx mediated by NOX2. Food Science and Human Wellness 2023;12:1081-1101. [DOI: 10.1016/j.fshw.2022.10.026] [Reference Citation Analysis]
2 Radu F, Potcovaru CG, Salmen T, Filip PV, Pop C, Fierbințeanu-Braticievici C. The Link between NAFLD and Metabolic Syndrome. Diagnostics (Basel) 2023;13. [PMID: 36832102 DOI: 10.3390/diagnostics13040614] [Reference Citation Analysis]
3 Ren W, Feng Y, Feng Y, Li J, Zhang C, Feng L, Cui L, Ran J. Relationship of liver fat content with systemic metabolism and chronic complications in patients with type 2 diabetes mellitus. Lipids Health Dis 2023;22:11. [PMID: 36694216 DOI: 10.1186/s12944-023-01775-6] [Reference Citation Analysis]
4 Hsu SJ, Huang HC, Pun CK, Chang CC, Chuang CL, Huang YH, Hou MC, Lee FY. Sodium-Glucose Cotransporter-2 Inhibition Exacerbates Hepatic Encephalopathy in Biliary Cirrhotic Rats. J Pharmacol Exp Ther 2022;383:25-31. [PMID: 35926870 DOI: 10.1124/jpet.122.001289] [Reference Citation Analysis]
5 Amodeo S, Mirarchi L, Seidita A, Citarrella R, Licata A, Soresi M, Iovanna JL, Giannitrapani L. EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy? Int J Mol Sci 2022;23:10120. [PMID: 36077515 DOI: 10.3390/ijms231710120] [Reference Citation Analysis]
6 Vairetti M, Colucci G, Ferrigno A. Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0. IJMS 2022;23:7894. [DOI: 10.3390/ijms23147894] [Reference Citation Analysis]
7 Yan M, Man S, Ma L, Gao W. Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. Metabolism 2022;134:155264. [PMID: 35810782 DOI: 10.1016/j.metabol.2022.155264] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345